Companies / VFY

VITRAFY LIFE SCIENCES LIMITED

ASX:VFYPharmaceuticals, Biotechnology & Life Sciences
76.2M shares on issueASX (delayed) · as of 28 July 2026$3.18price · delayed$244.0Mmarket cap · indicative
C
Dilution gradeprovisional — limited history

Share count grew 55% in 24 months; runway 4–8 quarters; 1 cash raise in 24 months

Cash runway7.3 quarters of funding
Share-count growth (24m)55.0%
Raise cadence (24m)1 cash raise
Options & rights overhang8.0% of shares
In-the-money supply0.1% of shares
Pending proposed issuesnone

VITRAFY LIFE SCIENCES LIMITED listed in November 2024 and therefore has a short disclosure history. Its ordinary share count rose 55.0% between February 2025 and July 2026, to 62M shares. The company raised capital once in the 24‑month window, raising A$32.0M via a placement in June 2026; total proceeds in that period are A$32.0M. Options and rights on issue could convert into 6M new shares, equal to 8.0% of the current share count, with the nearest expiry in June 2027 and 0% in the money. At the March 2026 quarter the company reported A$38.4M in available cash, sufficient for 7.3 quarters at its recent spending rate. No proposed securities issues (Appendix 3B) are pending.

AI-generated summary of this page's cited filings · updated 28 July 2026
Email me when this grade changes
Alerts are coming soon — this opens a pre-filled email that puts you on the list.
8.0%
Max option dilution
0.1%
ITM option dilution
1
Raises · last 12 months
7.3 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 76.2M per ASX (delayed) (28 July 2026).
66.5M70.0M73.6MDec 24Sept 25July 26Cash raise · 9 June 2026

Cash runway

7.3 qtrs
More than four quarters of funding at the recent spend rate.
$38.4M available cash at quarter ended 31 Mar 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds.
Paid plan
Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 31 Mar 2026.
Join the waitlist

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityTotal on issue afterSource
21 July 20262A · quoted issueVFY : ORDINARY FULLY PAID62.3MAppendix 2A
13 July 20263H · cancellationVFY : ORDINARY FULLY PAID62.3MAppendix 3H
9 July 20262A · quoted issueVFY : ORDINARY FULLY PAID62.3MAppendix 2A
8 July 20262A · quoted issueVFY : ORDINARY FULLY PAID62.3MAppendix 2A
17 June 20262A · quoted issueVFY : ORDINARY FULLY PAID61.5MAppendix 2A
Paid plan
Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Join the waitlist

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$32.0M
Placement
9 June 2026 COMPLETE
Paid plan
Full raise history
Issue price, discount, brokers, purpose and tranche detail for every raise on record.
Join the waitlist

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

8.0%
Total overhang · of current shares
0.1%
In the money · at current price
6.1M
Potential new shares
June 2027
Nearest expiry
Paid plan
Per-line options & expiry cliffs
Each option line — code, strike, expiry, quantity and ITM value — plus the expiry-cliff chart.
Join the waitlist

Director dealings

DateDirectorTypeSharesOptionsValueSource
9 July 2026Kate MunningsBuy2k——3Y notice
9 July 2026Brenton (Brent) OwensBuy2k——3Y notice
9 July 2026Brenton (Brent) OwensOther1.9M123k—3Y notice
Paid plan
Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Join the waitlist

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Sign up free — coming soon

Latest announcements

22 July 2026$PVitrafy enters a partnership with Hoxworth Blood Center
21 July 2026Application for quotation of securities - VFY
13 July 2026Notification of cessation of securities - VFY
9 July 2026Application for quotation of securities - VFY
8 July 2026Change of Director's Interest Notice - Correction
8 July 2026Change of Director's Interest Notices
8 July 2026Application for quotation of securities - VFY
8 July 2026Expiry of Voluntary Escrow Restrictions
7 July 2026Results of Oversubscribed Share Purchase Plan
18 June 2026$PVitrafy Share Purchase Plan Opens - SPP Offer Booklet
17 June 2026Cleansing Notice
17 June 2026Application for quotation of securities - VFY
11 June 2026Proposed issue of securities - VFY
11 June 2026$PVitrafy Equity Raising Presentation
11 June 2026$PVitrafy Placement Completion and SPP Announcement
9 June 2026$PTrading Halt
2 June 2026Vitrafy Investor Presentation
2 June 2026$PVitrafy enters a partnership with Vitalant Innovation Center
21 May 2026Phase 2 USAISR Platelet Results Investor Briefing
21 May 2026$PPhase 2 USAISR Platelet Results Investor Presentation

Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 July 2026.